Last reviewed · How we verify
25-OH Vitamin D3
25-OH Vitamin D3, marketed by Mariana Markell, is an established product in the vitamin D supplementation market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in competition post-patent expiry, which could impact revenue and market share.
At a glance
| Generic name | 25-OH Vitamin D3 |
|---|---|
| Also known as | (cholecalciferol) |
| Sponsor | Mariana Markell |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vitamin D Status in Young Medical Residents
- Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts
- Comparison of Maglumi X3 SNIBE With Other Analytical Methods in Laboratory Medicine for 25-(OH)D Quantification
- Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
- A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (PHASE4)
- Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients (NA)
- Effect of Vitamin D on Body Composition and Functionality of Older Adults (NA)
- Association Between Vitamin D Deficiency and Inflammatory Bowel Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 25-OH Vitamin D3 CI brief — competitive landscape report
- 25-OH Vitamin D3 updates RSS · CI watch RSS
- Mariana Markell portfolio CI